MNPR NASDAQ
Credit Risk of going bust: lower than 91% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Monopar Therapeutics Inc. would be worth roughly what it owes.
Total debt $108K against a stock market value of $473.5M.
Distance to default 14.45 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $54K (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' 36.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Wilmette, IL 60091
US
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Robinson Chandler | F-InKind | 597 | $92.59 | 2026-10-20 |
| STARR CHRISTOPHER M | S-Sale | 4,631 | $78.09 | 2026-10-01 |
| STARR CHRISTOPHER M | S-Sale | 2,970 | $78.82 | 2026-10-01 |
| STARR CHRISTOPHER M | S-Sale | 799 | $79.67 | 2026-10-01 |
| Cittadine Andrew | M-Exempt | 4,384 | — | 2026-09-30 |